Actively Recruiting
Combined Personalized Neoantigen-loaded Dendritic Cell Vaccine, PD-1 Inhibitor, and Radiotherapy Treatment for Advanced Non-Small Cell Lung Cancer After First-Line Therapy
Led by The First Affiliated Hospital of Nanchang University · Updated on 2024-12-30
10
Participants Needed
2
Research Sites
25 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a combined treatment approach for patients with advanced non-small cell lung cancer NSCLC whose disease has progressed after first-line therapy. The study aims to assess the objective response rate, disease control rate, safety, progression-free survival, and overall survival of a treatment combining a personalized tumor neoantigen-loaded dendritic cell DC vaccine, PD-1 inhibitor, and radiotherapy. Participants will first undergo personalized radiotherapy. Following radiotherapy, they will receive PD-1 inhibitor injections every three weeks and a total of 10 subcutaneous injections of the personalized DC vaccine over 21 weeks. The vaccine treatment includes a primary phase of 6 doses spaced weekly then biweekly, followed by a boost phase of 4 doses spaced three weeks apart. The treatment plan is tailored individually with doctors overseeing each step. During the study, participants will have regular follow-up visits every 6 weeks until study completion, including blood collection, physical exams, performance status assessments, imaging scans CTMRI, X-ray, and laboratory tests. The research team will monitor treatment effects, side effects, and disease progression over an average of 32 weeks, with longer survival follow-up up to 66 months. The total study duration allows for careful evaluation of treatment response and safety.
CONDITIONS
Brief Title
Neoantigen-loaded DC Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line Treatment
Research Team
Y
Yong Li, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here